Physiologically Speaking
OCTOBER 25, 2024
Greetings! Welcome to the Physiology Friday newsletter. Details about the sponsors of this newsletter including FSTFUEL electrolytes, Examine.com , and my book “VO2 Max Essentials ” can be found at the end of the post! Physiologically Speaking is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
Ken Grauer, MD
OCTOBER 25, 2024
The ECG in Figure-1 was obtained from a middle-aged man who presented with a 2 week history of progressively increasing CP ( C hest P ain ) with exertion. He had his most severe episode of CP the day before he was seen with this ECG. His CP was much less compared to the day before — but it had not yet completely resolved. An initial Troponin drawn less than 1 hour after the ECG in Figure-1 was recorded was over 10,000.
HCPLive
OCTOBER 25, 2024
These data demonstrated guselkumab’s success for the majority of patients with low body surface area (BSA) moderate plaque psoriasis and special site involvement.
Med Page Today
OCTOBER 25, 2024
(MedPage Today) -- On Sept. 14, 2000, at the age of 72, Lester Schwartz, a psychoanalyst working in New York City, underwent a simple operation for a benign fatty tumor in his stomach. He woke up the next morning in the hospital and realized he.
HCPLive
OCTOBER 25, 2024
Yee discussed how the data show a benefit in this hard-to-treat population, which was not seen in the heterogeneous FSGS group.
Cardiometabolic Health Congress
OCTOBER 25, 2024
The 19th Annual CMHC transformed Boston into the epicenter of cardiometabolic health and risk reduction from October 17-19, 2024, bringing together healthcare professionals from around the globe for the largest event of its kind in the US. The Hilton Boston Park Plaza became a hub of innovation, education, and collaboration, uniting nearly 500 clinicians under a shared mission: to redefine cardiometabolic care.
HCPLive
OCTOBER 25, 2024
Zand discussed interim 12-month findings from an open-label, phase 2 trial currently ongoing for patients with refractory primary focal segmental glomerulosclerosis.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
HCPLive
OCTOBER 25, 2024
On October 25, 2024, Kind Pharmaceutical announced receipt of FDA Orphan Drug Designation for AND017 in the treatment of sickle cell disease.
American College of Cardiology
OCTOBER 25, 2024
The following are key points to remember from a state-of-the-art review on the consequences of discontinuing long-term drug treatment in patients with heart failure and reduced ejection fraction (HFrEF).
HCPLive
OCTOBER 25, 2024
In this interview, Kwatra highlighted several key takeaways from his talks on prurigo nodularis, atopic dermatitis, and itch at the Fall Clinical Dermatology Conference.
Science Daily - Heart Disease
OCTOBER 25, 2024
Scientists have identified the protein GPNMB as a critical regulator in the heart's healing process after a heart attack.
HCPLive
OCTOBER 25, 2024
New FINEARTS-HF data shows that finerenone reduces albuminuria in patients with HFmrEF or HFpEF, but without significant eGFR changes.
Society of Thoracic Surgeons - Surgeon
OCTOBER 25, 2024
Event STS Leadership Institute 2025-26 kchalko Fri, 10/25/2024 - 10:48 Event dates Apr 1, 2025 – Jan 30, 2026 Location Zoom, Chicago, and New Orleans The STS Leadership Institute helps members in their first 15 years of practice to develop the skills necessary to lead teams in and out of the OR, strategize personal and professional goals, negotiate a career path, and influence change in the workplace.
HCPLive
OCTOBER 25, 2024
These data were presented at Fall Clinical, highlighting the reductions in Eczema Area and Severity Index scores and the overall long-term safety profile of tralokinumab-ldrm.
Dr. Paddy Barrett
OCTOBER 25, 2024
I am regularly asked to recommend books that have influenced my thinking on life and health. None of the books I recommend concern exercise, nutrition, sleep, medicine, or health. They are all books on what I call ‘Soul Span’ or how to live a life of meaning and purpose. Lifespan and healthspan are the domains of science and facts. Soul span is the domain of philosophy, literature and art.
HCPLive
OCTOBER 25, 2024
Yale's KAT-AKI trial found personalized EHR alerts for AKI management improved clinician actions but didn't reduce progression, dialysis, or mortality rates in patients.
Journal of the American Heart Association
OCTOBER 25, 2024
Journal of the American Heart Association, Ahead of Print. BackgroundMulticenter electronic health records can support quality improvement and comparative effectiveness research in stroke. However, limitations of electronic health record–based research include challenges in abstracting key clinical variables, including stroke severity, along with missing data.
HCPLive
OCTOBER 25, 2024
New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.
The American Journal of Cardiology
OCTOBER 25, 2024
Publication date: Available online 24 October 2024 Source: The American Journal of Cardiology Author(s): Fumiaki Yashima, Masanori Yamamoto, Shinichi Shirai, Norio Tada, Toru Naganuma, Masahiro Yamawaki, Futoshi Yamanaka, Kazuki Mizutani, Masahiko Noguchi, Hiroshi Ueno, Kensuke Takagi, Yohei Ohno, Masaki Izumo, Hidetaka Nishina, Hiroto Suzuyama, Kazumasa Yamasaki, Kenji Nishioka, Daisuke Hachinohe, Yasushi Fuku, Toshiaki Otsuka
HCPLive
OCTOBER 25, 2024
These long-term extension trial data from ADORING 3 highlight tapinarof cream’s efficacy in adults and children aged 2 years and older with atopic dermatitis.
The American Journal of Cardiology
OCTOBER 25, 2024
Publication date: Available online 24 October 2024 Source: The American Journal of Cardiology Author(s): Lars Jakobsen, Evald H Christiansen, Phillip Freeman, Johnny Kahlert, Karsten Veien, Michael Maeng, Julia Ellert, Steen D Kristensen, Martin K Christensen, Christian J Terkelsen, Troels Thim, Jens Flensted Lassen, Mikkel Hougaard, Ashkan Eftekhari, Rebekka V Jensen, Nicolaj B Støttrup, Jeppe G Rasmussen, Anders Junker, Lisette O Jensen
HCPLive
OCTOBER 25, 2024
These data from the ADapt study, presented at Fall Clinical, suggest improvements among patients with eczema given lebrikizumab-lbkz who had been previously treated with dupilumab.
The American Journal of Cardiology
OCTOBER 25, 2024
Publication date: Available online 24 October 2024 Source: The American Journal of Cardiology Author(s): David Leibowitz, Donna Zwas, Offer Amir, Israel Gotsman
HCPLive
OCTOBER 25, 2024
Panelists discuss how chronic spontaneous urticaria (CSU) affects approximately 0.5% to 1% of the population, predominantly impacting women and often presenting with variable wheals and angioedema.
NEJM Journal Watch - Cardiology
OCTOBER 25, 2024
A trio of trials provide more evidence for the safety and efficacy of SPCs to lower blood pressure.
HCPLive
OCTOBER 25, 2024
Panelists discuss how chronic spontaneous urticaria (CSU) affects approximately 0.5% to 1% of the population, predominantly impacting women and often presenting with variable wheals and angioedema.
HCPLive
OCTOBER 25, 2024
Panelists discuss how chronic spontaneous urticaria (CSU) is defined as the spontaneous appearance of wheals or angioedema lasting more than six 6 weeks, which can significantly impact patients' clinical health and psychosocial well-being.
HCPLive
OCTOBER 25, 2024
Panelists discuss the prevalence and clinical manifestations of chronic spontaneous urticaria (CSU), noting that it primarily affects individuals aged 20 to 40, with a prevalence of 0.5% to 1% in the general population and a higher incidence in women, while also addressing the variability in symptoms such as wheals, hives, and angioedema among patients.
HCPLive
OCTOBER 25, 2024
Panelists discuss how chronic spontaneous urticaria (CSU) significantly impacts patients’ overall well-being, both clinically and psychosocially, highlighting increased prevalence of depression, sleep disturbances, absenteeism, and adverse effects on professional life.
HCPLive
OCTOBER 25, 2024
At AAO 2024, Garg describes an analysis of the Phase 2/3 PHOTON trial evaluating the effect of DME treatment history on aflibercept 8 mg and 2 mg outcomes.
HCPLive
OCTOBER 25, 2024
In this interview segment, Del Rosso highlighted his Fall Clinical presentation takeaways covered in the talk ‘What’s New in the Medicine Chest - Part 2.
HCPLive
OCTOBER 25, 2024
After discontinuing therapy, treated participants still had an overall 13% reduction in the risk of kidney disease progression or cardiovascular death.
HCPLive
OCTOBER 25, 2024
At AAO 2024, Khurana discussed rapid visual and structural gains for uveitic macular edema with vamikibart, paving the way for Phase 3 trials.
HCPLive
OCTOBER 25, 2024
Herrington shared the carryover effects observed in the post-trial follow-up of the phase 3 EMPA-KIDNEY trial.
Expert insights. Personalized for you.
115 
Let's personalize your content